Statistics for Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration: Studies in Japan and the United States
Total visits
views | |
---|---|
Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration: Studies in Japan and the United States | 168 |
Total visits per month
views | |
---|---|
August 2024 | 0 |
September 2024 | 0 |
October 2024 | 0 |
November 2024 | 0 |
December 2024 | 0 |
January 2025 | 0 |
February 2025 | 0 |
File Visits
views | |
---|---|
Kunimoto_2019_evaluation.pdf | 283 |
java.util.UUID:a3aaa98e-8347-4a95-bff5-e29b41ad67f3 | 13 |
java.util.UUID:0817d518-909c-47b2-bb8f-975cb5b4f8ae | 2 |
Top country views
views | |
---|---|
United States | 129 |
Germany | 6 |
Ukraine | 3 |
Canada | 2 |
China | 2 |
Russia | 2 |
Czechia | 1 |
United Kingdom | 1 |
India | 1 |
Malaysia | 1 |
Pakistan | 1 |
Top city views
views | |
---|---|
Wilmington | 50 |
Houston | 17 |
Fairfield | 16 |
Ann Arbor | 8 |
Cambridge | 8 |
Jacksonville | 5 |
Kiev | 3 |
Kiez | 3 |
San Francisco | 2 |
Toronto | 2 |
Arnsberg | 1 |
Beijing | 1 |
Chicago | 1 |
Clayton | 1 |
Gunzenhausen | 1 |
Islamabad | 1 |
Moscow | 1 |
Nürnberg | 1 |
Pune | 1 |
Saint Petersburg | 1 |
Seattle | 1 |
Seremban | 1 |
Shenzhen | 1 |
Slapanice | 1 |
Washington | 1 |